Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY 10032, USA.
Department of Anesthesiology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Accid Anal Prev. 2024 Sep;204:107661. doi: 10.1016/j.aap.2024.107661. Epub 2024 May 30.
Polypharmacy (i.e., simultaneous use of two or more medications) poses a serious safety concern for older drivers. This study assesses the association between polypharmacy and hard braking events in older adult drivers.
Data for this study came from a naturalistic driving study of 2990 older adults. Information about medications was collected through the "brown-bag review" method. Primary vehicles of the study participants were instrumented with data recording devices for up to 44 months. Multivariable negative binomial model was used to estimate the adjusted incidence rate ratios (aIRRs) and 95 % confidence intervals (CIs) of hard-braking events (i.e., maneuvers with linear deceleration rates ≥0.4 g) associated with polypharmacy.
Of the 2990 participants, 2872 (96.1 %) were eligible for this analysis. At the time of enrollment, 157 (5.5 %) drivers were taking fewer than two medications, 904 (31.5 %) were taking 2-5 medications, 895 (31.2 %) were taking 6-9 medications, 571 (19.9 %) were taking 10-13 medications, and 345 (12.0 %) were taking 14 or more medications. Compared to drivers using fewer than two medications, the risk of hard-braking events increased 8 % (aIRR 1.08, 95 % CI 1.04, 1.13) for users of 2-5 medications, 12 % (aIRR 1.12, 95 % CI 1.08, 1.16) for users of 6-9 medications, 19 % (aIRR 1.19, 95 % CI 1.15, 1.24) for users of 10-13 medications, and 34 % (aIRR 1.34, 95 % CI 1.29, 1.40) for users of 14 or more medications.
Polypharmacy in older adult drivers is associated with significantly increased incidence of hard-braking events in a dose-response fashion. Effective interventions to reduce polypharmacy use may help improve driving safety in older adults.
同时使用两种或两种以上药物(即 多药治疗)会对老年驾驶员的安全造成严重威胁。本研究评估了多药治疗与老年驾驶员急刹车事件之间的关联。
本研究的数据来自对 2990 名老年人的自然驾驶研究。药物信息通过“棕色袋审查”方法收集。研究参与者的主要车辆配备了数据记录设备,最长可达 44 个月。采用多变量负二项式模型来估计与多药治疗相关的急刹车事件(即线性减速率≥0.4g 的操作)的调整后发病率比(aIRR)和 95%置信区间(CI)。
在 2990 名参与者中,有 2872 名(96.1%)符合本分析的条件。在入组时,有 157 名(5.5%)驾驶员服用的药物少于两种,904 名(31.5%)服用 2-5 种药物,895 名(31.2%)服用 6-9 种药物,571 名(19.9%)服用 10-13 种药物,345 名(12.0%)服用 14 种或更多药物。与服用少于两种药物的驾驶员相比,服用 2-5 种药物的驾驶员发生急刹车事件的风险增加 8%(aIRR 1.08,95%CI 1.04,1.13),服用 6-9 种药物的驾驶员风险增加 12%(aIRR 1.12,95%CI 1.08,1.16),服用 10-13 种药物的驾驶员风险增加 19%(aIRR 1.19,95%CI 1.15,1.24),服用 14 种或更多药物的驾驶员风险增加 34%(aIRR 1.34,95%CI 1.29,1.40)。
老年驾驶员的多药治疗与急刹车事件的发生率呈剂量反应关系显著增加。减少多药治疗的有效干预措施可能有助于提高老年驾驶员的驾驶安全性。